Aclaris Therapeutics (ACRS) Tops Q4 EPS by 17c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Nasdaq hits record high after softer jobs data tempers rate-hike bets
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Aclaris Therapeutis (ACRS): Eskata and Pipeline Should Drive Shares Higher - Cantor Fitzgerald
March 12, 2018 11:19 AM EDTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $50 price target on Aclaris Therapeutis (NASDAQ: ACRS), saying Eskata and the pipeline should drive share higher.
Chen commented, "Post a solid quarter of execution, and ahead of important catalysts for the company, we... More
Aclaris Therapeutics (ACRS) Announces U.S. Patent for JAK Inhibitor to Treat Hair Loss
March 9, 2018 8:02 AM ESTAclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,895,301, which is directed to methods related to the use and administration of a certain janus kinase (JAK) inhibitor for treating hair loss disorders.
U.S. Patent No. 9,895,301 covers the use of tofacitinib for inducing hair growth and for treating hair loss disorders such as alopecia areata and androgenetic alopecia (AGA), otherwise known as male/female pattern hair loss. Additional issued claims pertain to methods of... More
